{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:52:09Z","timestamp":1781531529191,"version":"3.54.5"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":148,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Amyloidosis refers to a heterogenous group of systemic diseases characterized by the presence of a misfolded protein that deposits as amyloid fibrils in the interstitium of organs and tissues. The vast majority of cases of cardiac involvement (cardiac amyloidosis\u2014CA) are due to immunoglobulin light chain (AL) amyloidosis, or transthyretin (ATTR) amyloidosis (either in its wild-type form\u2014ATTRwt, or variant\u2014ATTRv). The diagnostic workup of these diseases reflects the differences in terms of aetiology. Although imaging techniques represent fundamental tools in the diagnosis and follow-up of patients CA, they present several limitations. Cardiac biomarkers, particularly natriuretic peptides and troponins, overcome most of these limitations. They can be more sensitive in the detection of early phases of the disease but, overall, they currently represent the most powerful tool to define disease stage, organ response and disease progression. There is mounting evidence regarding the use of specific laboratory biomarkers to monitor treatment response. The information provided by advanced imaging techniques should be regarded as complementary and not as substitute for that provided by laboratory biomarkers, as only these can often be able to unveil the unseen.<\/jats:p>","DOI":"10.1093\/ehjimp\/qyag098","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:42:58Z","timestamp":1779882178000},"source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the unseen: navigating heart involvement in amyloidosis with biomarkers beyond the horizons of imaging"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-0961","authenticated-orcid":false,"given":"Giuseppe Damiano","family":"Sanna","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia , Viale Golgi, 19, Pavia 27100 ,","place":["Italy"]},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]},{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico De Nicola,\u00a0Sassari\u00a007100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia , Viale Golgi, 19, Pavia 27100 ,","place":["Italy"]},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Anna","family":"Di Simone","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]},{"name":"Division of Cardiology, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Carini","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]},{"name":"Division of Cardiology, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-1684","authenticated-orcid":false,"given":"Mario","family":"Nuvolone","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia , Viale Golgi, 19, Pavia 27100 ,","place":["Italy"]},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavino","family":"Casu","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico De Nicola,\u00a0Sassari\u00a007100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia , Viale Golgi, 19, Pavia 27100 ,","place":["Italy"]},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo , Viale Golgi 19,\u00a0Pavia\u00a027100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026061508521205700_qyag098-B1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaccao.2025.07.012","article-title":"Diagnostic performance of the new free light chain ratio in systemic amyloidosis","volume":"7","author":"Milani","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026061508521205700_qyag098-B3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/13506129.2024.2374904","article-title":"Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis","volume":"31","author":"Milani","year":"2024","journal-title":"Amyloid"},{"key":"2026061508521205700_qyag098-B4","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026061508521205700_qyag098-B5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026061508521205700_qyag098-B6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"2026061508521205700_qyag098-B7","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026061508521205700_qyag098-B8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00392-024-02522-2","article-title":"Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?","volume":"115","author":"Bellofatto","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026061508521205700_qyag098-B9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012146","article-title":"Myocardial inflammation in cardiac transthyretin amyloidosis: prevalence and potential prognostic implications","volume":"18","author":"M\u00fcller","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026061508521205700_qyag098-B10","doi-asserted-by":"crossref","first-page":"23313","DOI":"10.1038\/s41598-024-74289-5","article-title":"Myocardial inflammatory cells in cardiac amyloidosis","volume":"14","author":"Simon","year":"2024","journal-title":"Sci Rep"},{"key":"2026061508521205700_qyag098-B11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026061508521205700_qyag098-B12","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"2026061508521205700_qyag098-B13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ajh.27545","article-title":"Feasibility of a biomarker-based screening for pre-symptomatic AL amyloidosis in patients with intermediate\/high-risk MGUS","volume":"100","author":"Mangiacavalli","year":"2025","journal-title":"Am J Hematol"},{"key":"2026061508521205700_qyag098-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","article-title":"Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis: JACC: CardioOncology state-of-the-art review","volume":"6","author":"De Michieli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026061508521205700_qyag098-B15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026061508521205700_qyag098-B16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2024.10.013","article-title":"Biomarkers to predict abnormal technetium-99m pyrophosphate scans in patients with suspected transthyretin amyloidosis","volume":"7","author":"De Michieli","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026061508521205700_qyag098-B17","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026061508521205700_qyag098-B18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026061508521205700_qyag098-B19","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/CIRCULATIONAHA.124.071253","article-title":"Screening for cardiac involvement in carriers of pathogenic TTR variants: proposal for an approach based on high-sensitivity troponin","volume":"150","author":"Aimo","year":"2024","journal-title":"Circulation"},{"key":"2026061508521205700_qyag098-B20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2025.10.054","article-title":"Myocardial amyloid burden in transthyretin amyloidosis","volume":"87","author":"Sheikh","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B21","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026061508521205700_qyag098-B22","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"2026061508521205700_qyag098-B23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026061508521205700_qyag098-B24","first-page":"1598","article-title":"Limited utility of mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis\u2014analysis of a uniformly treated cohort of 1,275 patients","volume":"109","author":"Khwaja","year":"2024","journal-title":"Haematologica"},{"key":"2026061508521205700_qyag098-B25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JCO-25-02558","article-title":"New validated staging system for light chain (AL) amyloidosis with stage IIIC defining ultra-poor risk: AL international staging system","volume":"44","author":"Khwaja","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026061508521205700_qyag098-B26","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026061508521205700_qyag098-B27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.012816","article-title":"High-sensitivity cardiac troponin i for risk stratification in wild-type transthyretin amyloid cardiomyopathy","volume":"18","author":"De Michieli","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026061508521205700_qyag098-B29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.125.018862","article-title":"Global longitudinal strain for prognostic staging in wild-type transthyretin cardiac amyloidosis","volume":"19","author":"Debonnaire","year":"2026","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026061508521205700_qyag098-B30","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026061508521205700_qyag098-B31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061508521205700_qyag098-B32","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamacardio.2023.2010","article-title":"Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping","volume":"8","author":"Ioannou","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026061508521205700_qyag098-B33","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"key":"2026061508521205700_qyag098-B34","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","article-title":"Myocardial T1 and ECV measurement: underlying concepts and technical considerations","volume":"12","author":"Robinson","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026061508521205700_qyag098-B35","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jcmg.2025.07.017","article-title":"Changes in myocardial light chain amyloid burden after plasma cell therapy","volume":"18","author":"Benz","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026061508521205700_qyag098-B36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102766","article-title":"Monitoring disease progression in patients with transthyretin amyloid cardiomyopathy","author":"Garc\u00eda-Pav\u00eda","year":"2026","journal-title":"JACC Heart Fail"},{"key":"2026061508521205700_qyag098-B37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102549","article-title":"Outcome and disease progression in NYHA functional class I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis","volume":"13","author":"Sinigiani","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026061508521205700_qyag098-B39","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1093\/eurheartj\/ehaf412","article-title":"Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance","volume":"46","author":"Patel","year":"2025","journal-title":"Eur Heart J"},{"key":"2026061508521205700_qyag098-B40","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026061508521205700_qyag098-B41","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B42","first-page":"S0735-1097(26)00069-0","article-title":"Serum transthyretin before and after starting tafamidis as outcome predictors in ATTR cardiomyopathy","author":"Castiglione","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B43","first-page":"S0735-1097(26)00057-4","article-title":"Increase in serum transthyretin after tafamidis is associated with improved survival in transthyretin amyloid cardiomyopathy","author":"Ansari","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026061508521205700_qyag098-B44","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1038\/s41467-024-50231-1","article-title":"Determinants of transthyretin levels and their association with adverse clinical outcomes among UK biobank participants","volume":"15","author":"Shetty","year":"2024","journal-title":"Nat Commun"},{"key":"2026061508521205700_qyag098-B45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00392-025-02727-z","article-title":"Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis","volume":"115","author":"Sanna","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"2026061508521205700_qyag098-B46","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag048","article-title":"Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM","author":"Cappelli","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026061508521205700_qyag098-B47","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036755","article-title":"Predictors of early death in patients with wild-type transthyretin cardiac amyloidosis","volume":"14","author":"Milani","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026061508521205700_qyag098-B48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"2026061508521205700_qyag098-B49","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.117.029882","article-title":"NT-proBNP (N-Terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?)","volume":"137","author":"Stienen","year":"2018","journal-title":"Circulation"},{"key":"2026061508521205700_qyag098-B50","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC heart failure association","author":"Garcia-Pavia","year":"2026","journal-title":"Eur Heart J"},{"key":"2026061508521205700_qyag098-B51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/13506129.2016.1242480","article-title":"Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis","volume":"23","author":"Swiger","year":"2016","journal-title":"Amyloid"},{"key":"2026061508521205700_qyag098-B52","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis","volume":"131","author":"Kastritis","year":"2018","journal-title":"Blood"},{"key":"2026061508521205700_qyag098-B53","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/heartjnl-2024-324000","article-title":"Prognostic value of plasma big endothelin-1 in patients with light chain cardiac amyloidosis","volume":"110","author":"Chen","year":"2024","journal-title":"Heart"},{"key":"2026061508521205700_qyag098-B54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.24001","article-title":"Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Am J Hematol"},{"key":"2026061508521205700_qyag098-B55","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1179968","article-title":"Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study","volume":"10","author":"Nicol","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026061508521205700_qyag098-B56","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/CIRCULATIONAHA.123.067225","article-title":"Detection of circulating transthyretin amyloid aggregates in plasma: a novel biomarker for transthyretin amyloidosis","volume":"149","author":"Pedretti","year":"2024","journal-title":"Circulation"},{"key":"2026061508521205700_qyag098-B57","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ejhf.2339","article-title":"Integration of imaging and circulating biomarkers in heart failure: a consensus document by the biomarkers and imaging study groups of the heart failure association of the European Society of Cardiology","volume":"23","author":"Moura","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026061508521205700_qyag098-B58","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18f]-florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026061508521205700_qyag098-B59","first-page":"256","article-title":"Biomarkers of HFpEF: natriuretic peptides, high-sensitivity troponins and beyond","volume":"9","author":"Morfino","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026061508521205700_qyag098-B60","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"key":"2026061508521205700_qyag098-B61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"2026061508521205700_qyag098-B62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.16198","article-title":"Establishment of brain natriuretic peptide\u2014based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis","volume":"188","author":"Lilleness","year":"2020","journal-title":"Br J Haematol"}],"container-title":["European Heart Journal - Imaging Methods and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjimp\/advance-article-pdf\/doi\/10.1093\/ehjimp\/qyag098\/68429625\/qyag098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/1\/qyag098\/68429625\/qyag098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/1\/qyag098\/68429625\/qyag098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:52:24Z","timestamp":1781527944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjimp\/article\/doi\/10.1093\/ehjimp\/qyag098\/8697817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjimp\/qyag098","relation":{},"ISSN":["2755-9637"],"issn-type":[{"value":"2755-9637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1,1]]},"article-number":"qyag098"}}